Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

• Published in: Multiple sclerosis and related disorders Vol. 81; p. 105130
• Main Authors: Martin, Kayla, Srikanth, Priya, Kanwar, Anand, Falardeau, Julie, Pettersson, David, Yadav, Vijayshree
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2024
• Subjects: Adult; Aquaporin 4; Autoantibodies; Child; Demyelinating disease; Encephalitis; Humans; Myelin oligodendrocyte glycoprotein antibody-associated disease; Myelin-Oligodendrocyte Glycoprotein; Myelitis, Transverse - diagnostic imaging; Myelitis, Transverse - epidemiology; Neoplasm Recurrence, Local; Neurology; Neuromyelitis Optica; Neuromyelitis optica spectrum disorder; Northwestern United States; Optic Neuritis - diagnostic imaging; Optic Neuritis - epidemiology; Retrospective Studies; Northwestern United States; Demyelinating disease; Myelin oligodendrocyte glycoprotein antibody-associated disease; Neuromyelitis optica spectrum disorder; demyelinating disease; neuromyelitis optica spectrum disorder
• ISSN: 2211-0348; 2211-0356; 2211-0356
• DOI: 10.1016/j.msard.2023.105130

•There may be racial and ethnic differences in risk of relapsing disease in adult MOGAD.•Further studies in MOGAD should have a longer duration of follow-up to control for selection bias in monophasic subjects.•Compared to non-Hispanic White adults with MOGAD, Hispanics and non-Hispanic non-Whites may be at increased risk of relapsing MOGAD. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a newly described clinical entity comprised of isolated or recurrent attacks of optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), encephalitis, or seronegative NMOSD. Prior studies report that 30–80 % of children and adults with MOGAD go on to have relapses though there are no reliable predictors. The objectives of this study were to (1) describe the demographic, clinical, and radiographic patterns of MOGAD at our center and (2) identify possible predictors of relapsing disease. Single-center retrospective cohort study of pediatric and adult subjects with MOGAD evaluated at least once at our center between January 1, 2017 and September 30, 2022. Eligible subjects had a history of positive MOG-IgG and consistent clinical syndrome comprised of an initial attack of optic neuritis (ON), transverse myelitis (TM), ADEM, cerebral cortical encephalitis, seronegative neuromyelitis optica (simultaneous ON and TM), isolated brainstem or cerebellar syndrome, or other (not fitting into another group). Relapsing subjects or those remaining monophasic at 12 months were included in the analyses of predictors of relapsing disease. Covariates included age, sex, race/ethnicity, and index event phenotype. Unadjusted and adjusted risk ratios were calculated for pediatric and adult subjects. We describe the demographic, clinical, and radiographic characteristics of 58 subjects with MOGAD. Covariates from 48 subjects were analyzed for predictors of relapsing disease. In adults, Hispanics and non-White non-Hispanics were at increased risk of relapsing disease compared to non-Hispanic Whites [Adjusted RR 1.52 (95 % CI: 1.01, 2.30)]. There were no significant associations in the pediatric group. This study is the first to describe a cohort of MOGAD in the Pacific Northwest. Our findings highlight racial and ethnic differences in risk of relapsing MOGAD in adults. Further studies on racial and ethnic differences in MOGAD are needed to confirm these findings.